Chesley Taft & Associates LLC Vertex Pharmaceuticals Inc Transaction History

Chesley Taft & Associates LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 05, 2022	SELL	$177.01 - $223.45 $558,289 - $704,761	-3,154 Closed	0 $0
Q3 2021 Oct 05, 2021	SELL	$181.39 - $202.99 $119,717 - $133,973	-660 Reduced 17.3%	3,154 $572,000
Q1 2021 Apr 06, 2021	SELL	$207.02 - $241.31 $947,116 - $1.1 Million	-4,575 Reduced 54.54%	3,814 $821,000
Q4 2020 Jan 11, 2021	SELL	$207.01 - $276.09 $631,380 - $842,074	-3,050 Reduced 26.66%	8,389 $1.98 Million
Q3 2020 Oct 08, 2020	BUY	$255.65 - $303.1 $430,003 - $509,814	1,682 Added 17.24%	11,439 $3.11 Million
Q2 2020 Jul 08, 2020	BUY	$225.48 - $295.8 $1.75 Million - $2.29 Million	7,740 Added 383.74%	9,757 $2.83 Million
Q1 2020 Apr 15, 2020	SELL	$199.77 - $247.81 $4,994 - $6,195	-25 Reduced 1.22%	2,017 $480,000
Q4 2019 Jan 10, 2020	BUY	$166.71 - $223.91 $82,188 - $110,387	493 Added 31.83%	2,042 $447,000
Q3 2019 Oct 07, 2019	BUY	$166.23 - $187.09 $257,490 - $289,802	1,549 New	1,549 $262,000

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Chesley Taft & Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Chesley Taft & Associates LLC with notifications on news.